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IS THE PREVALENCE OF CELIAC DISEASE
INCREASED AMONG EPILEPTIC PATIENTS?
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ABSTRACT - Objective: To assess the prevalence of celiac disease (CD) among a group of epileptic patients
attending the Epilepsy Clinics of two general hospitals in the city of Brasilia (DF), Brazil. Method: Serum
samples were collected from 255 epileptic patients (119 children, 136 adults) originating from Epilepsy Clinics,
and from a control group composed by 4405 individuals (2034 children, 2371 adults) attending the Laboratory
of Clinical Analysis, for routine blood testing. The diagnosis of CD was determined by the antiendomysium
antibody (IgA-EMA) test and by small intestine biopsy. Results: two of the 255 epileptic patients (1:127) and
fifteen subjects from the control group (1:293) tested positive for the IgA-EMA assay. Conclusion: the prevalence
of CD was 2.3 times higher in epileptic patients than in controls (7.84 per 1000 versus 3.41 per 1000).
Although still not statistically significant, this result is highly suggestive of an increased prevalence of CD
among epileptic patients.
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A prevalência da doença celíaca é elevada entre pacientes com epilepsia?
RESUMO - Objetivo: Determinar a prevalência da doença celíaca (DC) num grupo de pacientes epilépticos
atendidos em ambulatórios de especialidade de dois hospitais gerais na cidade de Brasília (DF). Método:
Amostras de soro foram colhidas de 255 pacientes epilépticos (119 crianças, 136 adultos) e de uma população
formada por 4405 indivíduos (2034 crianças, 2371 adultos), atendidos no Laboratório de Análises Clínicas
para exames de rotina. O diagnóstico de DC foi estabelecido por meio do teste de anticorpos antiendomísio
(IgA-EMA) e por biópsia do intestino delgado. Resultados: dois dos 255 pacientes epilépticos (1:127) e quinze
indivíduos do grupo controle (1:293) apresentaram biópsia compatível e resultados positivos no teste IgA-
EMA. Conclusão: a prevalência de DC foi 2.3 vezes maior em pacientes epilépticos do que nos controles (7.84
per 1000 versus 3.41 per 1000). Apesar deste resultado não ser estatisticamente significativo pode, no entanto
ser considerado altamente sugestivo da existência de prevalência aumentada de DC entre pacientes epilépticos.
PALAVRAS-CHAVE: doença celíaca, enteropatia sensível ao glúten, epilepsia, prevalência.
Celiac disease (CD), also known as gluten-sensitive
enteropathy, is a lifelong disorder of variable severity
characterized by malabsorption and specific, though
not pathognomonic, lesions of the small intestinal
mucosa. Mucosal lesions are occasioned by sensitivity
to ingested wheat gluten or related barley or rye
proteins in genetically susceptible individuals. A strict
gluten free diet (GFD) results in regression of the
small intestinal abnormalities and a rapid relapse is
observed on reintroduction of dietary gluten. The
importance of genetic factors in the emergence of
CD is evidenced by the finding of an increased pre-
valence of the disease among first degree relatives1
and by a concordance of approximately 75 percent
among homozygous twins2. CD is strongly associated
with HLA class II antigens and over 95 percent of CD
patients express the HLA-DQ (α1*0501,β1*0201) he-
terodimer. Nonetheless only a minority of DQ2 posi-
tive subjects will develop the disorder since the ove-
rall importance of non-HLA still unidentified genes
is considered greater than that of HLA genes3. The
pathogenesis of CD is still not completely understood
but several lines of evidence point to a probable auto-
immune mechanism, triggered by an inappropriate
T-cell-mediated immune response against dietary
gluten. The enzyme tissue transglutaminase (tTG) is
the prominent, if not sole, target of the autoimmune
response4.
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Although, by definition CD is considered a disease
of the gastrointestinal tract and, indeed, the finding
of an abnormal jejunal mucosa is essential for the
diagnosis, its clinical manifestations can be extremely
variable. Typical forms, usually seen in childhood, are
mainly characterized by chronic diarrhea, bloating,
muscle wasting and impaired growth. In atypical
forms, generally seen in older children or in adults,
gastrointestinal complaints are less prominent and
extra-intestinal manifestations (e.g., short stature,
osteoporosis, delayed menarca, iron deficient ane-
mia) usually predominate. Silent forms, in which a
typical gluten-sensitive enteropathy is found in ap-
parently asymptomatic subjects, can also be
eventually detected. A more accurate anamnesis usu-
ally shows that many of these silent cases are affected
by minor complaints associated with a decreased psy-
chosocial well- being. CD is a life-long disorder and
its only effective treatment is a life-long GFD. To ma-
intain a diet that will last through life is a difficult
task, particularly in childhood and adolescence. The-
refore, it is extremely important to obtain a precise
diagnosis before starting the GFD. The first criteria
for the diagnosis of CD, established by the European
Society of Pediatric Gastroenterology and Nutrition
(ESPGAN) in 19705 were based on the results of three
sequential jejunal biopsies. During the last two de-
cade, with the advent of reliable serological assays
to detect the disease activity, the diagnosis of CD
was greatly facilitated. Given the high sensitivity and
specificity reported for these screening tools, es-
pecially for the antiendomysium (IgA-EMA)6 and anti-
transglutaminase antibody test (IgA-tTG)7, it is now
accepted a definitive diagnosis of CD based on posi-
tive serological results and a single intestinal biopsy
showing a flat or severely damaged mucosa, fol-
lowed by a favorable clinical and serological response
to gluten free diet (GFD)8. Serological assays, besides
helping in the diagnostic process, also made possible
an active search for new cases. The screening of the
general population using serological tests demons-
trated that CD is one of the commonest life-long
disorders. Nonetheless, there is a still prevalent lack
of awareness by health providers that frequently
results in delayed diagnosis. It has been shown that
the period of time between the onset of the first
symptoms and the final diagnosis can vary from 2
to more than 5 years9. In a recent European study,
the ratio between clinically diagnosed and undiag-
nosed cases of CD, the latter found by mass scre-
ening, was 1 to 710.
CD has been reported in association with various
diseases with known autoimmune basis, such as der-
matitis herpetiformis, type I diabetes, rheumatoid
arthritis, thyroiditis, and Sjogrens syndrome4. Ge-
netic disorders known for their association to other
autoimmune diseases, as Down syndrome11, and Tur-
ner syndrome12, also show a high CD prevalence. Du-
ring the last decades it has become increasingly evi-
dent that celiac patients can also manifest a variety
of disorders of the central and peripheral nervous
system. Neurological disorders described in associa-
tion with CD include, among others, sporadic and
progressive cerebellar ataxia, cerebral atrophy and
dementia, cerebral vasculitis, myopathy, peripheral
neuropathy and epilepsy13. During the last few de-
cades, several screening studies on the prevalence
of CD among epileptic patients14-16 were published,
and the existence of a syndrome, initially described
by Gobbi et al.17, characterized by the association of
CD, epilepsy and occipital calcifications is, by now,
well established and confirmed by several later se-
ries18,19 and case reports20,21. Apparently the preva-
lence of CD among epileptic patients is increased
although a chance association between epilepsy and
CD can not be excluded, since the prevalence of
asymptomatic CD in the general population, as pre-
viously cited, appears to be relatively high. The cau-
ses of the various neurological dysfunctions, inclu-
ding epilepsy, seen in association with CD are poorly
understood. Autoimmune mechanisms have been
considered a possible cause. The finding of other
autoantibodies in cases of refractory epilepsies as
e.g. glutamic acid decarboxylase (GAD) auto-anti-
bodies22, glutamate receptor (GluR3) antibodies23,
and anti-GM1 antibodies24 in some patients with re-
fractory or localization related epilepsies reinforces
the notion that epilepsy may, at times, be due to
autoimmune mechanisms.
This study was undertaken to assess the preva-
lence of CD among adults and children with epilepsy
attending the Seizure Clinics of two general hospitals
of the city of Brasilia (DF), Brazil.
METHOD
Between November 1998 and March 2002 serum sam-
ples were collected from adults attending the Epilepsy Cli-
nic of the Hospital de Base de Brasilia, and children atten-
ding the Pediatric Seizure Clinic of the Hospital Universitario
de Brasilia. Samples were stored at -80º C until testing.
The study design was approved by the Ethics Committee
of the University of Brasilia School of Health Sciences and
all adult participants or, in case of children, their parents,
received written and verbal information regarding the
objectives of the screening and gave informed consent.
Seizures were classified according to the scheme of the
International League against Epilepsy25. The etiology was
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not considered an excluding factor being admitted to the
study patients with idiopathic, symptomatic, and cryp-
togenic epilepsy. All patients admitted to the study had
suffered at least two unprovoked seizures. A population
composed by 4405 individuals (respectively, 2034 children,
and 2371 adults), attending the Laboratory of Clinical Ana-
lysis of the Brasilia University Hospital for routine blood
tests, was considered as control group. These patients were
part of an ongoing screening program for CD and, in order
to avoid selection bias, subjects with blood test requisitions
originating from pediatric or adult Gastroenterology Clinics
were excluded. The most frequent reasons for blood tes-
ting were routine health check-up, suspected or recurrent
infection, chronic ailments, metabolic diseases or pre-ope-
rative check-up. No inquire was performed among control
group subjects about the possible presence of epilepsy,
and this can be considered a minor bias. However, no ca-
ses of epilepsy were detected among the 15 control group
CD positive patients. Both, patients and controls, were
screened for celiac disease applying the antiendomysial
antibodies test (IgA-EMA), according to standard
immunofluorescence technique using fixed cryostat sec-
tions from the distal portion of primate esophagus (Cebus
apella) as antigen substrate6. Fluorescein-labeled goat anti-
body to human IgA was used as second antibody. All sera
were screened at a dilution of 1/5. Under the fluorescence
microscope the presence of a characteristic brilliant green
network pattern was taken as positive (Fig. 1). To confirm
the diagnosis of CD jejunal biopsy (children under three
years) or duodenal biopsy (older children and adults) were
suggested to IgA-EMA positive patients. Jejunal biopsies
were performed with a Watson pediatric capsule and sam-
ples were taken at the ligament of Treitz. The duodenal
biopsies were performed using an Olympus WM-30 video-
gastroscope (Olympus Keymed, UK), two to three samples
being taken, under direct visualization, from the second
portion of the duodenum.
RESULTS
Serum samples were obtained from 119 children
(49 girls and 70 boys, age range one to 14 years,
mean 7.97, median 8) and from 136 adults (72 men
and 64 women, age range 15 to 65, mean 30.27,
median 29). Of the total group of 255 epileptic pa-
tients, two patients disclosed a positive IgA-EMA test
(1:127). The control group was composed by 4405
individuals (2034 children, aged 1-14 years and 2371
adults aged 15-72 years). Eleven children and four
adults tested positive for the IgA-EMA assay. The ove-
rall prevalence of the control group was 1:293.
The two positive epileptic patients were a 33-year-
old woman and a 3-year-six-month-old boy. Jejunal
biopsy, performed in both patients, revealed the ty-
pical aspect of celiac enteropathy (complete villous
atrophy with hypertrophic criptae and increased
number of intraepithelial lymphocytes) (Fig. 2). Both
celiac patients had history of difficult to control sei-
zures. The adult patient had a long lasting history of
complex partial seizures, starting when she was 15-
years-old. She had taken in the past, several different
antiepileptic drugs (AED) but her seizures never had
been completely controlled. Her CT scan revealed
significant mesial temporal sclerosis on the left
Fig 2. The childs intestinal biopsy specimen showing total villous
atrophy (flat mucosa) with crypt hypertrophy and increased
number of intraepithelial lymphocytes.
Fig 1. Adult patients positive immunofluorecence test, showing
characteristic honeycomb-like brilliant pattern of primate (Cebus
apella) esophagus smooth muscle bundles (magnification x400).
The childs test displayed a similar pattern.
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hemisphere. She was on high dose of carbamazepine
(65mg/kg/day), but still having several seizures,
almost every week. In spite of the high dose of AED
and a good compliance with the medication, her
blood levels were consistently on the low therapeutic
range arising the suspicion of malabsorption. She
was underweight, and complained of depression,
poor disposition and a chronic lack of appetite but
did not disclose any symptoms related to the gas-
trointestinal tract.
The child, that never had previously suffered any
seizure and had a negative family history for epilepsy,
was admitted to the hospital emergency room due
to a first generalized tonic-clonic seizure, that pro-
gressed, days later, to frequent short lasting complex
partial seizures and by brief and frequent (more than
fifty times a day) atonic attacks. Tonic-clonic seizures
also continued to recur sporadically, mainly during
sleep. Both physical and neurological examination
were normal aside a moderate degree of unstea-
diness and attention deficit. His electroencepha-
logram was suggestive of Lennox-Gastaut syndrome,
disclosing a slow background intermixed by frequent
sharp-and-slow-wave complexes. The remaining diag-
nostic work-up, which included CT-scan, MRI, scre-
ening for inborn errors of metabolism and determi-
nation of CSF IgG index and electrophoresis for pre-
sence of oligoclonal bands was completely normal.
DISCUSSION
More than three decades have elapsed since the
first descriptions of neurological dysfunction and epi-
lepsy in patients suffering celiac disease26 but the
mechanisms involved in the sudden emergence and
progression of the various disorders of the central
and peripheral nervous system are still elusive. Stu-
dies on the possible association between celiac di-
sease and epilepsy are scarce. Some of the studies
have shown an increased prevalence of epilepsy
among celiac patients27,28. Some, inversely, have
shown increased prevalence of CD among epileptic
patients14,15, while others failed to show any dif-
ference29.In this study, the prevalence of CD was 2.3
times higher in patients with epilepsy than in controls
(7.84 per 1000 in patients with epilepsy versus 3.41
per 1000 in controls), Although these results could
be considered suggestive of an increased prevalence
of CD among patients with epilepsy, applying the
Fisher exact test to determine the statistical signifi-
cance of the difference between the two groups the
conclusion is that the difference is still not statistically
significant [prevalence ratio = 2.3; CI = 95% (0.53
10.02); p-value = 0.23]. Perhaps an increase in the
sample size, possibly through a multicenter study, may
confirm the existence of a higher and statistically sig-
nificant prevalence of CD among epileptic patients.
Taking our findings into account and reviewing
previously published studies, some general obser-
vations concerning the association between epilepsy
and CD can be brought forward: (a) in many epileptic
patients CD is asymptomatic or disclose only mild or
atypical features14,15; (b) epilepsy without cerebral
calcifications, may be an early manifestation of CD,
with calcifications developing later30; (c) early iden-
tification and treatment of CD may reverse the
tendency to epilepsy and probably to the develop-
ment of calcifications16; (d) seizures seen in associa-
tion with CD are frequently difficult to control and,
at least in some cases, this is due to poor AEDs
absorption resulting from the concurrent entero-
pathy17; (e) if CD is not precociously diagnosed, epi-
lepsy will have propensity to progress in severity, evol-
ving to a degree in which, even the introduction of
GFD will fail to ameliorate the clinical picture17; (f)
although generalized forms of epilepsy are seen that,
at times, rapidly evolve to a severe and progressive
encephalopathy suggestive of Lennox-Gastaut
syndrome31, partial complex seizures with involve-
ment of the occipital lobes are more frequent16.
In conclusion, a greater attention is needed to
the possible coexistence of CD in epileptic patients.
Although a systematic screening for CD in all epileptic
patients seems to be, at the present time, neither
practical nor cost-effective, it seems reasonable to
screen at least all patients with complex partial
seizures, especially when associated with occipital
paroxysms and resistance to drug therapy.
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